Following an abbreviated submission:
nevirapine prolonged release tablets (Viramune®) are accepted for use in NHS Scotland.
Indication under review: in combination with other anti-retroviral medicinal products for the treatment of HIV-1 infected adults, adolescents, and children three years and above and able to swallow tablets.
Once daily dosing with the nevirapine prolonged release formulation demonstrated non-inferior efficacy to the immediate release nevirapine formulation at 48 weeks in both treatment-naïve and treatment-experienced patients. When combined with other HIV therapies the once daily formulation may provide a more convenient dosing schedule for patients.
Download detailed advice39KB (PDF)
- Medicine name:
- nevirapine (Viramune)
- SMC ID:
- In combination with other anti-retroviral medicinal products, for the treatment of HIV-1 infected adults, adolescents, and children three years and above and able to swallow tablets.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Submission type
- Date advice published
- 13 February 2012